{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:54:11Z","timestamp":1790096051590,"version":"4.0.1"},"reference-count":9,"publisher":"SAGE Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JND"],"published-print":{"date-parts":[[2020,9,18]]},"abstract":"<jats:p>Immune-related adverse events (irAE) during the administration of immune-checkpoint inhibitors (ICIs) become more evident due to the increased use of these therapies. To remind the importance of early recognition of this phenomenon, we report a paradigmatic case characterized by severe systemic inflammatory myopathy and severe cardiac involvement that abruptly precipitated in an untoward ending after one single dose of Pembrolizumab.<\/jats:p>","DOI":"10.3233\/jnd-200504","type":"journal-article","created":{"date-parts":[[2020,7,3]],"date-time":"2020-07-03T14:01:34Z","timestamp":1593784894000},"page":"511-514","source":"Crossref","is-referenced-by-count":5,"title":["Severe inflammatory myopathy in a pulmonary carcinoma patient treated with Pembrolizumab: An alert for myologists"],"prefix":"10.1177","volume":"7","author":[{"given":"L.","family":"Peverelli","sequence":"first","affiliation":[{"name":"ASST Lodi, Ospedale Maggiore di Lodi, Neurology Unit, Lodi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"De Rosa","sequence":"additional","affiliation":[{"name":"Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Domina","sequence":"additional","affiliation":[{"name":"ASST Lodi, Ospedale Maggiore di Lodi, Neurology Unit, Lodi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Ciscato","sequence":"additional","affiliation":[{"name":"Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sita","sequence":"additional","affiliation":[{"name":"ASST Lodi, Ospedale Maggiore di Lodi, Oncology Unit, Lodi, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Velardo","sequence":"additional","affiliation":[{"name":"Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.P.","family":"Comi","sequence":"additional","affiliation":[{"name":"Neuromuscular and Rare Diseases Unit, Department of Neuroscience, Foundation IRCCS Ca\u2019 Granda Ospedale Maggiore Policlinico, Milano, Italy"},{"name":"Dino Ferrari Centre, Neuroscience Section, Department of Pathophysiology and Transplantation (DEPT), University of Milan, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","reference":[{"issue":"6230","key":"10.3233\/JND-200504_ref1","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1126\/science.aaa8172","article-title":"The future of immune checkpoint therapy","volume":"348","author":"Sharma","year":"2015","journal-title":"Science"},{"issue":"9948","key":"10.3233\/JND-200504_ref2","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S0140-6736(14)60958-2","article-title":"Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial","volume":"384","author":"Robert","year":"2014","journal-title":"Lancet Lond Engl"},{"issue":"5","key":"10.3233\/JND-200504_ref3","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1634\/theoncologist.2015-0498","article-title":"FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1","volume":"21","author":"Sul","year":"2016","journal-title":"The Oncologist"},{"issue":"3","key":"10.3233\/JND-200504_ref4","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1093\/annonc\/mdw655","article-title":"Pembrolizumab induced bulbar myopathy and respiratory failure with necrotizing myositis of the diaphragm","volume":"28","author":"Haddox","year":"2017","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"14","key":"10.3233\/JND-200504_ref5","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1212\/WNL.0000000000007235","article-title":"Neuromuscular adverse events associated with anti-PD-1 monoclonal antibodies: Systematic review","volume":"92","author":"Johansen","year":"2019","journal-title":"Neurology"},{"key":"10.3233\/JND-200504_ref6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.jaut.2019.03.005","article-title":"Inflammatory myopathy associated with PD-1 inhibitors","volume":"100","author":"Seki","year":"2019","journal-title":"J Autoimmun"},{"issue":"11","key":"10.3233\/JND-200504_ref7","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.2169\/internalmedicine.1956-18","article-title":"Pembrolizumab-induced Ocular Myasthenia Gravis with Anti-titin Antibody and Necrotizing Myopathy","volume":"58","author":"Onda","year":"2019","journal-title":"Intern Med Tokyo Jpn"},{"issue":"4","key":"10.3233\/JND-200504_ref8","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1097\/CJI.0000000000000196","article-title":"PD-1 Inhibitor-associated Myopathies: Emerging Immune-mediated Myopathies","volume":"41","author":"Liewluck","year":"2018","journal-title":"J Immunother Hagerstown Md"},{"issue":"2","key":"10.3233\/JND-200504_ref9","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1056\/NEJMra1703481","article-title":"Immune-Related Adverse Events Associated with Immune Checkpoint Blockade","volume":"378","author":"Postow","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuromuscular Diseases"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/JND-200504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T23:49:30Z","timestamp":1777506570000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/JND-200504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,18]]},"references-count":9,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.3233\/jnd-200504","relation":{},"ISSN":["2214-3599","2214-3602"],"issn-type":[{"value":"2214-3599","type":"print"},{"value":"2214-3602","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,18]]}}}